Understanding how specific cells help close the urethra in newborn boys
Defining the role of Sf1 in urethral closure
This study is looking at how certain cells in the penis help with the closure of the urethra, which is important for understanding hypospadias, a condition that affects baby boys, and it hopes to find better ways to prevent and treat it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11086291 on NIH RePORTER |
What this research studies
This research investigates the role of a specific cell type in the penis that expresses a key enzyme involved in hormone signaling, which is crucial for the proper closure of the urethra. The study focuses on understanding how these cells communicate with surrounding tissues and how they respond to hormones like testosterone and dihydrotestosterone. By exploring the mechanisms behind urethral closure, the research aims to uncover the causes of hypospadias, a common birth defect affecting newborn boys. The findings could lead to better prevention and treatment strategies for this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are newborn boys diagnosed with hypospadias or those at risk of developing this condition.
Not a fit: Patients who are not newborn boys or those without a diagnosis of hypospadias may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for hypospadias, potentially reducing the incidence of this birth defect.
How similar studies have performed: While the specific role of Sf1 in urethral closure is being explored for the first time, similar research on hormone signaling in development has shown promising results in understanding other birth defects.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Amato, Ciro Maurizio — University of Missouri-Columbia
- Study coordinator: Amato, Ciro Maurizio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.